Investor Relations
Valuation · Deck · Financial Model
1yfe Health Investment Materials
Comprehensive valuation analysis, investor deck, and Fortune 100-grade financial model. Pre-revenue startup valued using 5 standard methods.
Static Full Report (Printable + Crawler-Readable)
Full valuation, deck, and financial model as static HTML — readable by search engines, AI tools, and printable to PDF.
Triangulated Valuation Range
$1.95M — $39.50M
5-Method Average: $10.67M · Midpoint: $20.73M
$1.95M
Berkus
$4.11M
Scorecard
$4.50M
Risk Factor
$39.50M
VC Method
$3.27M
Cost-to-Dup
Berkus Method
Assigns up to $500K per success factor. Max $2.5M for pre-revenue startups.
$68B TAM growing 9.4% CAGR. FDA Category 1 reclassification (Feb 2026) creates legal clarity. Physician-prescribed DTC model validated by Hims/Ro ($1B+ revenue). Near-max score.
Not a prototype — production-grade platform: 40+ pages, 25 database entities, 30+ backend functions, 3 AI agents, Stripe payments, real-time subscriptions, genetic matching, predictive health engine, wearable integration, community forum, affiliate MLM system, full admin portal. This is a complete product.
Technical founder built the entire platform solo — demonstrates exceptional execution velocity. Medical advisory pipeline active. Needs C-suite hires (CMO, COO, medical director) which is typical pre-revenue. Deducted for solo-founder risk.
FDA-registered 503A pharmacy partnerships established. IMLC physician network for telehealth prescribing across 43+ states. Affiliate program with multi-tier commission structure built. No enterprise contracts yet — deducted accordingly.
Platform is live and functional with Stripe integration (test mode). 5 subscription tiers priced and configured. Lead capture, health intake forms, and checkout flows built. No reported revenue — pre-launch phase. Score reflects readiness without traction.
Scorecard Method (Bill Payne)
Compares to median pre-money valuation of funded health-tech startups ($3.5M baseline). Each factor scored as % of average.
Baseline: $3.50M · Weighted Multiplier: 1.18x
Solo founder with extraordinary technical execution (built entire platform). Offset by lack of co-founder, no C-suite, no medical director yet. Score: 95% (slightly below average for solo-founder risk).
$68B TAM growing 9.4% CAGR. FDA Category 1 reclassification is a once-in-a-decade regulatory tailwind. GLP-1 revolution proved the DTC prescription model. 77M Baby Boomers entering peak longevity demand. Score: 140% (well above average).
Far beyond typical seed-stage prototype. 40+ production pages, 3 AI agents, genetic matching, predictive health, 14-source intelligence engine, dose tracking, biomarker dashboards, wearable integration, telemedicine, pharmacy fulfillment pipeline, community forum. Massive technical moat. Score: 150%.
No direct AI-first peptide platform competitor exists. Hims/Ro focused on GLP-1/hair/ED, not peptide protocol optimization. Anti-aging clinics lack technology. Research chem sites lack medical legitimacy. Score: 115%.
Affiliate program built with MLM commission structure, lead capture active, SEO content infrastructure in place. However, no proven CAC or LTV data, no paying customers, no marketing spend history. Score: 80%.
Will need seed round for team, marketing, pharmacy inventory, and HIPAA certification. Standard capital requirements for this stage. Score: 100% (neutral).
Exceptional timing — post-FDA reclassification creates immediate legal clarity. First-mover advantage in AI-personalized peptide protocols. Proprietary AI agents and protocol intelligence engine represent defensible IP. Score: 140%.
Risk Factor Summation
Adjusts baseline by ±$250K–$500K across 12 risk categories based on actual platform state and market conditions.
Baseline: $3.50M
Management Risk
$-250K · Solo founder — exceptional executor but single point of failure. Needs co-founder/C-suite.
Stage of Business
$-500K · Pre-revenue, pre-launch. Platform complete but no paying customers or revenue data.
Legislation / Political
+$500K · Major tailwind: FDA Category 1 reclassification (Feb 2026) legalizes compounded peptides through 503A pharmacies.
Manufacturing Risk
+$250K · Asset-light model — partners with FDA-registered 503A pharmacies. No in-house compounding liability.
Sales & Marketing Risk
$-250K · No proven CAC/LTV metrics. Affiliate program built but untested. Content/SEO infrastructure ready but unvalidated.
Funding / Capital Risk
$-250K · Bootstrapped to date. Will require institutional capital to scale team and marketing. No committed investors yet.
Technology Risk
+$500K · Platform is production-complete: 40+ pages, 30+ backend functions, 3 AI agents, Stripe integration, real-time data. Very low tech risk.
Litigation Risk
Neutral · Standard health-tech risk. Compliant disclaimers, consent tracking, and audit logging built in. Neutral.
International Risk
Neutral · US-only strategy. Coverage in 43+ states via IMLC. No international complexity. Neutral.
Reputation Risk
+$250K · Physician-prescribed model, GMP pharmacy partners, HIPAA compliance framework, consent tracking, and audit logging all build institutional trust.
Potential Lucrative Exit
+$500K · Digital health M&A averaging $7B+ annually. Hims at $3B+ market cap validates DTC health model. Strategic acquirer pool includes telehealth, pharma, and wellness platforms.
Competition Risk
+$250K · No direct competitor combines AI protocol optimization + physician prescribing + DTC delivery. Significant first-mover advantage.
Venture Capital Method
Works backward from projected exit value to determine justified pre-money valuation today.
Cost-to-Duplicate
Floor valuation: what it would cost a team to rebuild the current platform from scratch at market rates.
Floor estimate only. Does not account for future revenue potential, brand equity, network effects, or AI intellectual property value.
Confidential — For Authorized Investors Only
This document contains confidential and proprietary information of 1yfe Health. It is intended solely for the use of authorized investors and their advisors. Do not distribute, copy, or disclose any contents without prior written consent. All projections are forward-looking and subject to material risks and uncertainties. This does not constitute an offer to sell or solicitation to buy any securities.